首页> 外文期刊>Molecular cancer research: MCR >Identification of Cdk1-LATS-Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells
【24h】

Identification of Cdk1-LATS-Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells

机译:鉴定CDK1-LAT-PIN1作为癌细胞抗微管蛋白药物反应中的新型信号轴

获取原文
获取原文并翻译 | 示例
           

摘要

The Hippo pathway is a signaling cascade that plays important roles in organ size control, tumorigenesis, metastasis, stress response, stem cell differentiation, and renewal during development and tissue homeostasis and mechanotransduction. Recently, it has been observed that loss of the Hippo pathway core component LATS (large tumor suppressor) or overexpression of its downstream targets YAP and its paralog TAZ causes resistance of cancer cells to anti-tubulin drugs. However, YAP and TAZ mediates anti-tubulin drug-induced apoptosis independent of its upstream regulator LATS and the Hippo pathway. Thus, the underlying molecular mechanism of how LATS is involved in the anti-tubulin drug response remains unknown. Proteomic approaches, SILAC and BioID, were used to identify the isomerase Pin1 as a novel LATS-interacting protein after anti-tubulin drug treatment. Treatment with anti-tubulin drugs activated cyclin-dependent kinase 1 (CDK1), which phosphorylates LATS2 at five S/T-P motifs that functionally interact with the WW domain of Pin1 and inhibit its antiapoptotic function. Thus, these data identify Cdk1 and Pin1 as a novel upstream regulator and downstream mediator, respectively, of LATS in antitubulin drug response. Further studies on this novel Cdk1-LATS-Pin1 signaling axis will be important for understanding the molecular mechanisms of drug resistance and will provide useful information for targeting of this pathway in the future. (C) 2018 AACR.
机译:Hippo途径是一种信号级联,在发挥体内控制,肿瘤瘤,转移,应力反应,干细胞分化和更新中起重要作用,在发育和组织稳态和机械调节期间。最近,已经观察到,河马途径核心组分LAT(大肿瘤抑制器)或其下游靶叶片的过表达损失以及其副病毒性葡萄球菌菌导致癌细胞对抗微管蛋白药物的抗性。然而,YAP和TAZ介导抗微管蛋白药物诱导的细胞凋亡,独立于其上游调节器LAT和河马途径。因此,LAT的潜在分子机制如何参与抗微管蛋白药物反应仍然未知。蛋白质组学方法,硅酸和生物肽,用于在抗微管蛋白药物处理后将异构酶PIN1鉴定为新型LAT - 相互作用蛋白质。用抗小管蛋白药物的处理活性细胞周期蛋白依赖性激酶1(CDK1),其在五个S / T-P图中磷酸化LATS2,其在功能上与PIN1的WW结构域相互作用并抑制其抗曝光功能。因此,这些数据分别将CDK1和PIN1识别为新型上游调节器和下游介体,在抗胰岛素药物反应中的LAT。关于这部小型CDK1-LAT-PIN1信号轴的进一步研究对于了解耐药性的分子机制,将来提供有用的信息,以便将来瞄准该途径。 (c)2018年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号